MedicalCommunications GmbH recalled 474 units of HEYEX PACS software on September 9, 2025. The software may inaccurately report measured values, posing risks to patient care. Users should stop using the software immediately and follow recall instructions.
Potential that the measured value may be smaller than the actual area.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact MedicalCommunications GmbH or your healthcare provider for instructions. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves the Ashvins variant HEYEX 2 / HEYEX PACS software, with versions ranging from 2.6.0 (Build 2088) to 2.6.8 (Build 2220). The software was distributed nationwide in the United States.
The software may report measured values that are smaller than the actual area. This could lead to misdiagnosis or incorrect treatment decisions, posing serious risks to patient safety.
As of the recall date, there have been no reported injuries or incidents associated with the software malfunction. However, the potential for harm remains high.
Patients and healthcare providers must stop using the HEYEX PACS software immediately. Follow the manufacturer’s recall instructions by contacting MedicalCommunications GmbH or your healthcare provider.
For further assistance, reach MedicalCommunications GmbH via email as provided in the recall notification.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.